nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.09.2003 | Review Article

Imaging of large vessel vasculitis with ¹⁸FDG PET: illusion or reality? A critical review of the literature data

verfasst von: Tarik Belhocine, Daniel Blockmans, Roland Hustinx, Johan Vandevivere, Luc Mortelmans

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2003

Einloggen, um Zugang zu erhalten

Abstract

Fluorine-18 fluorodeoxyglucose positron emission tomography (¹⁸FDG PET) plays a major role in the management of oncology patients. Owing to the singular properties of the glucose tracer, many patients suffering from non-malignant diseases such as inflammatory or infectious diseases may also derive clinical benefit from the appropriate use of metabolic imaging. Large vessel vasculitides such as giant cell arteritis and Takayasu arteritis are other examples that may potentially extend the field of ¹⁸FDG PET indications. The purpose of the present article is to assess the feasibility of metabolic imaging in vasculitis on the basis of the current literature data. In particular, the clinical context and the ¹⁸FDG imaging patterns seen in patients with large vessel vasculitis are analysed in order to identify potential indications for metabolic imaging.

Delbeke D. Oncological applications of FDG PET Imaging. J Nucl Med 1999; 40:1706–1715.PubMed

Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Mazière B. FDG accumulation and tumor biology. Nucl Med Biol 1998; 25:317–322.CrossRefPubMed

Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33:1972–1980.PubMed

Ishimori T, Saga T, Mamede M, Kobayashi H, Higashi T, Nakamoto Y, Sato N, Konishi J. Increased¹⁸F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation. J Nucl Med 2002; 43:658–663.

Jones HA, Cadwallader KA, White JF, Uddin M, Peters AM, Chilvers ER. Dissociation between respiratory burst activity and deoxyglucose uptake in human neutrophil granulocytes: implications for interpretation of¹⁸F-FDG PET images. J Nucl Med 2002; 43:652–657.

Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG-PET imaging: physiologic and artifactual fluorodeoxyglucose accumulation. J Nucl Med 1996; 36:441–446.

Haberkorn U, Strauss LG, Dimitrakopoulou A, Engenhart R, Oberdorfer F, Ostertag H, Romahn J, van Kaick G. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991; 32:1485–1490.PubMed

Lewis PJ, Salama A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994; 35:1647–1649.PubMed

Stumpe KD, Dazzi H, Schaffner A, von Schulthess GK. Infection imaging using whole-body FDG PET. Eur J Nucl Med 2000; 27:822–832.CrossRefPubMed

10.

Bakheet SM, Powe J, Ezzat A, Rostom A. F-18-FDG uptake in tuberculosis. Clin Nucl Med 1998; 23:739–742.PubMed

11.

Franzius C, Biermann M, Hulskamp G, Frosch M, Roth J, Sciuk J, Schober O. Therapy monitoring in aspergillosis using F-18 FDG positron emission tomography. Clin Nucl Med 2001; 26:822–832.CrossRef

12.

Lie JT. Illustrated histopathological classification criteria for selected vasculitis syndromes. American Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum 1990; 33:1074–1087.PubMed

13.

Hunder GG. Classification/diagnostic criteria for GCA/PMR. Clin Exp Rheumatol 2000; 18 (4 Suppl 20):S4–S5.

14.

Arend WP, Michel BA, Bloch DA, et al. the American college of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33:1129–1134.PubMed

15.

Jennette JC, Falk R, Andrassy K, et al. Nomenclature of systemic vasculitis. Proposal of an international conference. Arthritis Rheum 1994; 37:187–192.PubMed

16.

Gross WL, Trabandt A, Reinhold-Keller E. Diagnosis and evaluation of vasculitis. Rheumatology 2000; 39:245–252.CrossRefPubMed

17.

Salvani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347:261–271.CrossRefPubMed

18.

Blockmans D, Knockaert D, Maes A, De Caestecker J, Stroobants S, Bobbaers H, Mortelmans L. Clinical value of¹⁸F-fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis 2001; 31:191–196.CrossRef

19.

Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Gonzalez-Louzao C, Rodriguez-Ledo P. Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum 2001; 30:249–256.CrossRefPubMed

20.

Lambert M, Hachulla E, Hatron PY, Perez-Cousin M, Beregi JP, Warembourg H, Devulder B. Takayasu's arteritis: vascular investigations and therapeutic management. Experience with 16 patients. Rev Med Interne 1998; 19:878–884.CrossRefPubMed

21.

Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 1995; 122:502–507.PubMed

22.

Liu G, Shupak R, Chiu BK. Aortic dissection in giant-cell arteritis. Semin Arthritis Rheum 1995; 25:160–171.PubMed

23.

Greene GM, Lain D, Sherwin RM, Wilson JE, McManus BM. Giant cell arteritis of the legs. Clinical isolation of severe disease with gangrene and amputations. Am J Med 1986; 81:727–733.PubMed

24.

Klein RG, Hunder GG, Stanson AW, Sheps SG. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 1975; 83:806–812.PubMed

25.

Nordborg E, Bengtsson BA. Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy. BMJ 1989; 299:549–550.PubMed

26.

Lie JT. Aortic and extracranial large vessel giant cell arteritis: a review of 72 cases with histopathologic documentation. Semin Arthritis Rheum 1995; 24:422–431.PubMed

27.

Kerr GS. Takayasu's arteritis. Rheum Dis Clin North Am 1995; 21:1041–1058.PubMed

28.

Fauci AS. The vasculitis syndromes. In: Braunwald E, Fauci AS, Kasper DL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine 2001, 15th edn. New York: McGraw-Hill; 2001:1956–1968.

29.

Ishikawa K. Natural history and classification of occlusive thromboaortopathy (Takayasu's disease). Circulation 1978; 57:27–34.PubMed

30.

Blockmans D, Maes A, Stroobants S, Nuyts J, Bormans G, Knockaert D, Bobbaers H, Mortelmans L. New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. Rheumatology (Oxf) 1999; 38:444–447.

31.

Blockmans D, Stroobants S, Maes A, Mortelmans L. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 2000; 108:246–249.CrossRefPubMed

32.

Belhocine T, Kaye O, Delanaye P, Corman C, Baghaie M, Deprez M, Daenen F, De Barsy C, Beckers C, Gomez P, Hustinx R, Foidart-Willems J, Demonty J, Malaise M, Rigo P. Maladie de Horton et atteintes artérielles extra-temporales: utilité de la tomographie par émission de positons au¹⁸FDG. A propos de trois observations et revue de la littérature. Rev Med Interne 2002; 23:1–8.PubMed

33.

De Winter F, Petrovic M, Van de Wiele C, Vogelaers D, Afschrift M, Dierckx RA. Imaging of giant cell arteritis: evidence of splenic involvement using FDG positron emission tomography. Clin Nucl Med 2000; 25:633–634.CrossRefPubMed

34.

Turlakow A, Yeung HW, Pui J, Macapinlac H, Liebovitz E, Rusch V, Goy A, Larson SM. Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med 2001; 161:1003–1007.CrossRefPubMed

35.

Hara M, Goodman PC, Leder RA. FDG-PET finding in early-phase Takayasu arteritis. J Comput Assist Tomogr 1999; 23:16–18.PubMed

36.

Meller J, Grabbe E, Becker W, Vosshenrich R. Value of F-18 FDG hybrid camera PET and MRI in early Takayasu aortitis. Eur Radiol 2003; 13:400–405.PubMed

37.

Meller J, Strutz F, Siefker U, Scheel A, Sahlmann CO, Lehmann K, Conrad M, Vosshenrich R. Early diagnosis and follow-up of aortitis with [¹⁸F]FDG PET and MRI. Eur J Nucl Med 2003; 30:730–736.

38.

Fahey FH. Positron emission tomography instrumentation. Radiol Clin North Am 2001; 39:919–929.PubMed

39.

Fayad ZA, Fuster V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. Circ Res 2001; 89:305–316.PubMed

40.

Yun M, Yeh D, Araujo LI, Jang S, Newberg A, Alavi A. F-18 FDG uptake in the large arteries. A new observation. Clin Nucl Med 2001; 26:314–319.PubMed

41.

Yun M, Jang S, Cucchiara A, Newberg AB, Alavi A.¹⁸F-FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med 2002; 32:70–76.PubMed

42.

Rudd JHF, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, Johnström P, Davenport AP, Kirkpatrick PJ, Arch BN, Pickard JD, Weissberg PL. Imaging atherosclerotic plaque inflammation with [¹⁸F]-fluorodeoxyglucose positron emission tomography. Circulation 2002; 105:2708–2711.CrossRefPubMed

43.

Sakalihasan N, Van Damme H, Gomez P, Rigo P, Lapiere CM, Nusgens B, Limet R. Positron emission tomography (PET) evaluation of abdominal aortic aneurysm (AAA). Eur J Vasc Endovasc Surg 2002; 23:431–436.CrossRefPubMed

44.

Lederman RJ, Raylman RR, Fisher SJ, Kison PV, San H, Nabel EG, Wahl RL. Detection of atherosclerosis using a novel positron-sensitive probe and¹⁸F-fluorodeoxyglucose (FDG). Nucl Med Commun 2001; 22:747–753.PubMed

45.

Barron JT, Barany M, Gu L, Parrillo JE. Metabolic fate of glucose in vascular smooth muscle during contraction induced by norepinephrine. J Mol Cell Cardiol 1998; 30:709.CrossRefPubMed

46.

Vallabhajosula S, Fuster V. Atherosclerosis: imaging techniques and the evolving role of nuclear medicine. J Nucl Med 1997; 38:1788–1796.PubMed

47.

Vallabhajosula S, Machac J, Knesaurek K, et al. Imaging atherosclerotic macrophage density by positron emission tomography using F-18-fluorodeoxyglucose (FDG). J Nucl Med 1996; 37:1788–1796.

48.

Helft G, Worthley SG, Zhang ZY, Tang C, Rodriguez O, Wei T, Fallon JT, Fayad ZA, Mahac J, Buschsbaum M, Fuster V, Badimon JJ. Non-invasive in vivo imaging of atherosclerotic lesions using fluorine-18 deoxyglucose (18-FDG) PET correlates with macrophage content in a rabbit model [abstract]. Circulation 1999; 100 (Suppl I):I-311.

49.

Mochizuki Y, Fujii H, Yasuda S, Nakahara T, Takahashi W, Ide M, Koide S, Shohtsu A. FDG accumulation in aortic walls. Clin Nucl Med 2001; 26:68–69.CrossRefPubMed

50.

Hoogendoorn EH, Oyen WJG, van Dijk APJ, van der Meer JWM. Pneumococcal aortitis, report of a case with emphasis on the contribution to diagnosis of positron emission tomography using fluorinated deoxyglucose. Clin Microbiol Infect 2003; 9:73–76.CrossRefPubMed

51.

Weyand CM, George BB. Giant cell arteritis: new concepts in pathogenesis and implications for management. Am J Ophthalmol 1997; 123:392–395.PubMed

52.

Hotchi M. Pathological studies on Takayasu arteritis [review]. Heart Vessels Suppl 1992; 7:11–17.PubMed

53.

Ross R. Atherosclerosis, an inflammatory disease. N Engl J Med 1999; 340:115–126.PubMed

54.

Numano F, Kishi Y, Tanaka A, Ohkawara M, Kakuta T, Kobayashi Y. Inflammation and atherosclerosis. Atherosclerotic lesions in Takayasu arteritis [review]. Ann N Y Acad Sci 2000; 902:65–76.PubMed

55.

Numano F. Vasa vasoritis, vasculitis and atherosclerosis. Int J Cardiol 2000; 75 Suppl 1:S1–S8; discussion S17–S19.

56.

Kayser M, Younge B, Björnsonn J, Goronzy JJ, Weyland CM. Formation of new vasa vasorum in vasculitis. Am J Pathol 1999; 155:765–774.PubMed

57.

Rittner HL, Kaiser M, Brack A, Szweda LI, Goronzy JJ, Weyand CM. Tissue-destructive macrophages in giant cell arteritis. Circ Res 1999; 84:1050–1058.PubMed

58.

Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis 1999; 147:213–225.CrossRefPubMed

59.

Disdier P, Pellissier JF, Harle JR. Significance of isolated vasculitis of the vasa vasorum of temporal artery biopsy. J Rheumatol 1994; 21:258–260.PubMed

60.

Wilcox JN, Scott NA. Potential role of the adventitia in arteritis and atherosclerosis. Int J Cardiol 1996; 54 Suppl 1:21–35.

61.

Deichen JT, Prante O, Gack M, Schmiedehausen K, Kuwert T. Uptake of [¹⁸F]fluorodeoxyglucose in human monocyte-macrophage in vitro. Eur J Nucl Med 2003; 30:267–273.

62.

Zhuang HM, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, Mozley PD, Rossman MD, Albelda SM, Alavi A. Dual time point 18F-FDG imaging for differentiating malignant from inflammatory process. J Nucl Med 2001; 42:1412–1417.PubMed

63.

Zhao S, Kuge Y, Tsukamoto E, Mochizuki T, Kato T, Hikosaka K, Hosokawa M, Tamaki N. Effects of insulin and glucose loading on FDG uptake in experimental malignant tumors and inflammatory lesions. Eur J Nucl Med 2001; 28:730–735.

64.

Service RF. New dynamic duo: PET, MRI, joined for the first time. Science 1996; 272:1423.PubMed

65.

Dizendorf EV, Treyer V, von Schulthess GK, Hany TF. Application of oral contrast media in coregistered positron emission tomography–CT. AJR 2002; 179:477–488.

Titel: Imaging of large vessel vasculitis with 18FDG PET: illusion or reality? A critical review of the literature data
verfasst von: Tarik Belhocine
Daniel Blockmans
Roland Hustinx
Johan Vandevivere
Luc Mortelmans
Publikationsdatum: 01.09.2003
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2003
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-003-1209-y

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2003

Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells

Dosimetry in leakage of 188Re-DTPA during intracoronary balloon brachytherapy

99mTc-Demotate 1: first data in tumour patients—results of a pilot/phase I study

Breast imaging: a correlative atlas

[Tc(CO)3]+ chemistry: a promising new concept for SPECT?

[Tc(CO)3]+ chemistry: a promising new concept for SPET?